Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. - Wikidata - awgldk - TriplyDB

Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

http://www.wikidata.org/entity/Q33710581

about

Metformin for endometrial hyperplasia Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma Role of contrast-enhanced ultrasound (CEUS) in the diagnosis of endometrial pathology.Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome Discovery and validation of methylation markers for endometrial cancer.Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.The diagnosis and treatment of endometrial cancer: progress and controversies.Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia.Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.Metformin for endometrial hyperplasia: a Cochrane protocol Safety after extended repeated use of ulipristal acetate for uterine fibroids Coexisting carcinoma in endometrial hyperplasia: does more risk factor mean better discrimination?Management of endometrial precancers.High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma.Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.Endometrial cancer, types, prognosis, female hormones and antihormones.Association between cytochrome P450 1A1 MspI polymorphism and endometrial cancer risk: a meta-analysis.Surgical management of abnormal uterine bleeding in fertile age women.Through thick and thin: a pictorial review of the endometrium.Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.Lymph node dissection in atypical endometrial hyperplasia.Sox9 overexpression in uterine epithelia induces endometrial gland hyperplasia.Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS).Quantitative assessment of the association between CYP1A1 A4889G polymorphism and endometrial cancer risk.Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development.Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.Predictors of malignancy in endometrial polyps: study of 421 women with postmenopausal bleeding.Metformin for endometrial hyperplasia.A case of endometrial carcinoma in a long-term Levonorgestrel Intrauterine System (LNG 52 mg-IUS) user.Transvaginal ultrasound examination of the endometrium in postmenopausal women without vaginal bleeding.Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients

P2860

Q26472029-87BF43C8-F6D4-4229-B5C4-2AD87ADC841A Q26768659-88A760CB-2FFE-4A96-988C-2A118F1C4D09 Q26770804-DDEAA969-66C2-4FCD-87AF-983F8571DED8 Q30576718-2BE3C0A5-0B77-4FD7-8226-68B6F0D44115 Q33996492-F51449F5-EC96-48C4-8429-8194DF97E0BB Q34020931-57480AB0-4DA5-45CF-BB28-49EEE96643D9 Q34579547-D851E788-515D-473E-AE64-5F7793015A36 Q34718198-8B93D425-AD53-425B-91DC-0CD172D22531 Q35176084-FFA20EB6-0136-48A9-B730-8F8A6AAD3C4C Q35196619-948E57AE-A1B1-4A9B-9E4B-4421F4D2B7B0 Q35198210-5CF967A6-8653-404B-8BD1-2097F3AECCF9 Q35235853-4854BF64-ADEA-4ABC-BF8F-6E3E391C7D81 Q36099979-1B49FA8B-AAA2-44CB-98CF-44CBDCC4B3F4 Q36105494-D3D117A9-D099-4AC1-B71B-D29CFA154ABE Q36299562-1AC53F63-97CD-4F7E-9B2A-943EC2E573F8 Q36547004-0F7893A9-77F9-4351-8F29-203BEFD7ECB4 Q37238537-DDC20D08-ACCA-4333-A5D9-348D82E3087F Q37627214-A3FDD3C9-78F1-453F-AEAA-771D510F039E Q37702500-EBA2D7A2-F201-4856-8BD8-AB4576E9F2AA Q37855938-7450A8DC-C45B-441B-9FE2-3BF06013BACA Q38406045-9700EC36-9C66-4F6A-8FC7-861488CD589C Q38559857-80E9F3F7-3A2F-4EB0-8320-83AC5DF01054 Q38979219-E578A3AE-2AA8-4AD4-859C-3F9905F9611F Q39658317-705F0559-4F00-4636-8F7D-1D43AB5DCEBB Q41522497-548E3385-87A1-4AEC-AE00-7F7CEEFE7432 Q41640253-A577D44E-7C9D-4B66-982C-F22FB6E2AB3D Q41878396-C612B52C-98A6-49AA-B165-7588E5C099C7 Q43559477-BB1FEC35-4B52-476E-A14A-70661E040124 Q44187810-52325E79-5F5E-4683-899F-BDC3840D1A57 Q45410745-8555B916-90AD-4D9C-93B7-B3BDFE686E4B Q46098313-BF9FD04E-AC03-494E-AA70-4BA7A8D5A260 Q47345402-A7BABE27-F63D-4AEF-B5D7-2B8384DBF2A3 Q47404052-FB2A4289-9170-4C13-AD4A-7A4875852F2C Q51023198-A435FE65-319C-45BE-B4F2-07DCE69EABF0 Q53240789-77FEFDE7-1EA2-4445-A4D7-07FE2A1D2430 Q57819009-5E3E2052-B543-4229-9E48-CFDD3A6CBDBC Q58746068-268B9474-007B-429B-9CB5-E54201418E86

P2860

Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

http://www.wikidata.org/entity/Q33710581

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@ast

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@en

type

label

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@ast

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@en

prefLabel

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@ast

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@en

P1433

Q33710581-856C32BA-128A-41F0-ACB7-05D68ACD125E

P1476

Q33710581-A1ED86A5-F208-423E-8F4F-D347E635AC95

P2093

Q33710581-09DA8228-F876-42D7-AA3A-564BB4745810

Q33710581-7D89EE39-F536-42BE-A4F0-66C84D129596

Q33710581-7E282550-224C-4B04-928F-2A75592FD584

Q33710581-AA3191BD-8EC3-4331-B9E3-353513D0E3B1

Q33710581-ABF09330-B75B-4622-83E0-0AD454DFA309

Q33710581-ACB8D68C-CFCF-4A2D-926E-E6BEBC904A9A

Q33710581-CCFC15D3-BBD0-44F6-A6B5-7FD1E33DA896

Q33710581-D9A60AC4-D3CE-4489-B3E5-243B8737765C

Q33710581-F6BB317F-ED62-42B9-B394-B6F1FB17D18E

P2860

Q33710581-117C8E08-EAEC-48B3-9AA4-810AE1FE4C80

Q33710581-25131D99-D0B6-4864-BF9F-44681FC96ECE

Q33710581-2E05E372-BB46-4AFE-8090-9BA4E1484F8E

Q33710581-2FA62AF6-BF8A-4222-9185-D81830709F0D

Q33710581-4AB1A866-05C7-4E50-8FF8-69F35B48EF85

Q33710581-6DDF5663-C5ED-4D85-8008-F6B3113EDDD7

Q33710581-7995A9AB-0A1F-4D6A-9564-C2F789CC2212

Q33710581-89D6AEBD-4FA5-4686-98F7-9D7A91903894

Q33710581-8D8ECA65-20F1-45D0-AA78-FC2F793B686B

Q33710581-9A96DCD5-6B53-4244-A396-5BE2ED8CAF32

P304

Q33710581-4FA6C488-89E6-46FE-907C-C3704AEE9721

P31

Q33710581-605D79C0-550C-4431-9973-A55050E7C0CE

P356

Q33710581-39D67C82-78EB-4F00-A169-ADF36BD3CF2F

P407

Q33710581-B439D2F2-93A4-4F1C-8C64-11850A08FE1F

P433

Q33710581-7E99B2ED-CE01-4711-9F9C-81B38EC307BD

P478

Q33710581-7FF64880-59AD-49A1-A20C-B0C173AB21D6

P50

Q33710581-5F1766A3-341C-42FE-9BF2-C532B75447EC

P577

Q33710581-E2FD5B43-5634-44CB-989D-1894F382423E

P698

Q33710581-DFA2BCCE-295D-4BF0-B879-F1B7861E2B43

P932

Q33710581-9D7EA46E-C28D-4B58-8D20-B6A05233DD85

P356

JCO.2009.24.1315

P1433

Journal of Clinical Oncology

P1476

Absolute risk of endometrial c ...... with endometrial hyperplasia.

@en

P2093

Andrew G Glass

http://www.w3.org/2001/XMLSchema#string

Brenda B Rush

http://www.w3.org/2001/XMLSchema#string

Brigitte M Ronnett

http://www.w3.org/2001/XMLSchema#string

Bryan Langholz

http://www.w3.org/2001/XMLSchema#string

Douglas A Richesson

http://www.w3.org/2001/XMLSchema#string

James V Lacey

http://www.w3.org/2001/XMLSchema#string

Mark E Sherman

http://www.w3.org/2001/XMLSchema#string

Máire A Duggan

http://www.w3.org/2001/XMLSchema#string

Olga B Ioffe

http://www.w3.org/2001/XMLSchema#string

P2860

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

Problems in the differential diagnosis of endometrial hyperplasia and carcinoma.

Endometrial hyperplasia: is it time for a quantum leap to a new classification?

Optimal management of endometrial hyperplasia.

Sampling strategies in nested case-control studies.

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

My approach to the interpretation of endometrial biopsies and curettings.

Endometrial hyperplasia/adenocarcinoma. a conventional approach.

The management of endometrial hyperplasia: an evaluation of current practice.

Building a research consortium of large health systems: the Cancer Research Network.

P304

788-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.1315

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Nilanjan Chatterjee

P577

2010-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20065186

http://www.w3.org/2001/XMLSchema#string

P932

2834395

http://www.w3.org/2001/XMLSchema#string